ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
Professor Desire Collen Will Remain as Chairman of the Board and
ThromboGenics NV announced that Patrik De Haes, MD, currently Chief Operating Officer, has been appointed to succeed Professor Desire Collen as the Company's new Chief Executive Officer onSeptember 1, 2008. At the next General Shareholders Meeting Dr. De Haes will be proposed to become a member of the Board of Directors of ThromboGenics. In the mean time, he will be invited to the Board meetings.
Dr. De Haes, 50, has considerable international experience across the biotechnology and healthcare sectors spanning more than 20 years. For the last 18 months, Dr. De Haes has been ThromboGenics' Chief Operating Officer overseeing the Company';s daily operations. During this period, he has been a key member of the management team that has achieved a number of transforming milestones for ThromboGenics. These include initiating the clinical development of the Company's unique anti-cancer agent TB-403, and the subsequent development deal for potentially up toEUR500 million with Roche. Dr. De Haes has also been a major contributor to the development strategy of ThromboGenics' lead product, microplasmin, which the Company plans to advance into Phase III clinical trials in early 2009 for the treatment of a number of important eye diseases.
Prior to joining ThromboGenics, Dr. De Haes was Head of the Global Insulin Infusion Business at Roche Diagnostics in Bern, Switzerland, and a member of the Executive Committee of Roche Diabetes Care. From 1996 to 2003, he was President and CEO of Disetronic Medical Systems Inc., Minneapolis, USA, a medical device company.
Dr. De Haes has also held senior positions in the pharmaceutical industry with Sandoz Pharma (now part of Novartis). Dr. De Haes is a Medical Doctor, University of Leuven, Belgium, and holds a corporate MBA,University of St Thomas,Minneapolis,USA.
Other news from the department people
